Becton, Dickinson and Company is a global medical technology leader founded in 1897 and headquartered in Franklin Lakes, New Jersey. It manufactures medical supplies, devices, laboratory equipment, and diagnostic products used across hospitals and life-science research. With a market capitalization of roughly $51 billion, BDX is one of the largest names in the healthcare equipment and supplies sector.
The $225 level carries special significance because it is the company's all-time high, reached in July 2023 at about $225.79. After that peak, shares gave back substantial ground, trading as low as roughly $127.59 within the trailing 52-week period before staging a powerful recovery. The question now facing investors is whether the stock can complete that round trip and push to a new record.
BDX has rallied strongly from its lows, with a roughly 26% one-year total return through early September 2026. Shares recently traded near $187, just beneath the 52-week high of about $193.07. The stock's beta is notably low—around 0.26—reflecting its reputation as a comparatively stable, defensive holding within the healthcare space.
Fundamentally, the company delivered a solid quarter, reporting earnings per share (EPS) of $3.23 for its fiscal third quarter, ahead of the roughly $3.14 consensus estimate, on revenue of $4.98 billion that rose 5.4% year over year. Management has guided fiscal 2026 EPS to a range of $12.62 to $12.72, which implies a forward price-to-earnings (P/E) multiple of only about 15 times at current levels—well below the broader market. The company also pays a quarterly dividend, translating to a roughly 2.2% yield.
Several catalysts could support a sustained push toward $225. First, BDX has identified a set of high-growth platforms—including drug-delivery systems for GLP-1 and biologic therapies, pharmacy automation such as its Pyxis Pro line, peripheral vascular products, and advanced patient monitoring—that together represent meaningful exposure to durable healthcare trends. Analysts at firms including Jefferies, Citi, and UBS have cited these franchises in issuing Buy ratings and price targets of $205 to $210.
Second, the planned separation of the Biosciences and Diagnostic Solutions business could create a more focused, higher-growth core company and potentially unlock shareholder value. Third, the company's shareholder-focused capital approach—combining dividend growth with share repurchases—provides a level of downside support that could help sustain upward momentum during market pullbacks.
The path to $225 is not without friction. China's volume-based procurement program has pressured pricing for medical-device makers, and BDX expects the majority of its China revenue to be affected. Vaccine-related demand has also softened, and management has flagged transitory headwinds around its Alaris infusion-pump franchise. Tariffs and trade policy add further uncertainty to the international revenue base.
Execution risk around the business separation is another concern. Divestitures of this scale carry integration and cost implications, and several analysts have noted that consistent mid-single-digit organic growth in reported results may still be 12 to 18 months away. RBC Capital, for instance, has characterized the near-term outlook as constructive but remains on the sidelines with a Hold rating and a $190 target.
Wall Street's view is generally positive but measured. The consensus rating is a Moderate Buy, with the average 12-month price target clustering near $190 to $196. Targets range from as low as about $150 to a high of $225, with notable recent moves including Bank of America raising its target to $200, Jefferies to $210, and Barclays to $204.
The critical observation is that the average analyst target sits roughly where the stock already trades, while the $225 level represents the very top of the Street's range. For BDX to reach $225, it would likely need to deliver not only consistent earnings beats but also tangible evidence that the separation and its growth platforms are accelerating revenue—something the market has yet to fully price in.
From a technical analysis standpoint, the first hurdle is the 52-week high near $193. A decisive move through that zone would put the stock in uncharted territory relative to its recent range and could open a path toward the $200 psychological level. Beyond that, the $225.79 all-time high represents the major long-term resistance level and the ultimate confirmation of a full recovery. On the downside, the $180 area and the roughly $160–165 zone have acted as support during the recovery.
For investors seeking a data-driven way to monitor setups like the one described above, Tickeron's AI Daily Buy/Sell Signals offer an additional lens. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface new opportunities, track existing positions, and identify changing market trends more efficiently. While no tool can predict price moves with certainty, integrating AI-based signals with fundamental research may help investors act with greater discipline.
Reaching $225 is plausible but demanding. The strongest arguments in favor are the company's low forward valuation, improving procedure volumes, high-growth product franchises, and a shareholder-friendly capital program. Against those stand persistent pricing headwinds in China, vaccine softness, and the execution risks tied to the pending separation.
Because the consensus analyst target remains below $225, achieving that level would require BDX to exceed current expectations rather than simply meet them. Investors should monitor the business separation timeline, the trajectory of organic revenue growth, and whether the stock can first clear the $193 52-week high. A sustained breakout above that level would meaningfully improve the odds, while failure to hold recent gains could signal that the recovery has stalled short of the record.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.21% | ||
| COO - BDX | 55% Loosely correlated | +0.65% | ||
| BAX - BDX | 51% Loosely correlated | +0.86% | ||
| TMO - BDX | 50% Loosely correlated | +1.34% | ||
| MMSI - BDX | 50% Loosely correlated | -0.61% | ||
| CNMD - BDX | 48% Loosely correlated | +0.63% | ||
More | ||||
| Ticker / NAME | Correlation To BDX | 1D Price Change % |
|---|---|---|
| BDX | 100% | +0.21% |
| Pharmaceuticals: Other industry (51 stocks) | 34% Loosely correlated | -0.41% |
| Pharmaceuticals industry (156 stocks) | 3% Poorly correlated | -0.82% |